The investigational agent, Descartes-08, is currently in a phase 2 study evaluating its use in patients with high-risk multiple myeloma. Preliminary results are expected in June 2023.Ĭartesian Therapeutics, based in Gaithersburg, Maryland, is developing the first CAR-T cell therapy to potentially treat newly diagnosed multiple myeloma. Poseida’s product, provisionally named P-BCMA-ALLO1, is currently in a phase 1 study evaluating its safety in patients with relapsed/refractory multiple myeloma. Allogeneic products carry an increased risk of host-graft and graft-versus-host reactions, but they can be created more easily to meet off-the-shelf demand. Instead of using the patient’s own cells, the allogeneic version of CAR-T uses T cells from donors to create CAR-T cells for use in multiple patients. Poseida Therapeutics, a San Diego biotech company, is developing an allogeneic version of CAR-T therapy. CAR-T therapy is complicated and expensive the price of the primary treatment and the associated treatment typically exceeds $500,000. Typically, CAR-T-cell therapies target CD19 antigens or B-cell maturation antigens (BCMAs). Millions of CAR-altered T cells are grown in the laboratory, then infused back into the patient, where they seek out and bind to antigens on cancer cells and destroy them. These proteins are called chimeric antigen receptors (CARs). The T cells, which are the mainstays of the body’s immune system, are collected from the patient’s blood and re-engineered in a laboratory to produce proteins on their surfaces that recognize and attach to specific antigens on the surface of cancer cells. Off the shelfĬAR-T therapy has involved using the patient’s own T cells to attack cancer cells. A cohort of newer treatments featuring innovative mechanisms of action are currently under development, including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies.
will die from the multiple myeloma.Ĭlinicians and patients have a growing number of treatment options for multiple myeloma from which to choose, both for patients whose disease comes back after responding to treatment (relapse) and isn’t responding to treatment (refractory). The National Cancer Institute estimates that approximately 34,500 cases will be diagnosed this year and that 12,640 people in the U.S. Although relatively rare, accounting for less than 2% of all cancer cases each year, multiple myeloma is the second most common blood cancer in the United States. Multiple myeloma is a form of cancer characterized by the proliferation of plasma cells in the bone marrow.
0 kommentar(er)
